More Globe Newswire

View Older Stories View Newer Stories

May 23, 2024 05:51PM Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti
May 23, 2024 05:49PM Parks! America, Inc. Announces Glass Lewis Recommends Parks! America Shareholders Vote “FOR” Each of the Director Nominees Recommended by the Board
May 23, 2024 05:49PM CORRECTION – The Herzfeld Caribbean Basin Fund, Inc. Announces Distribution in Stock and Cash
May 23, 2024 05:41PM Mountain America Credit Union Named Utah's Leading SBA Lender for Third Consecutive Year
May 23, 2024 05:40PM Stockholder Alert: Robbins LLP Informs Investors that a Class Action has been filed Against Cambium Networks Corporation (CMBM)
May 23, 2024 05:33PM 3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6
May 23, 2024 05:30PM Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
May 23, 2024 05:30PM Premier Health Reports 2024 Second Quarter Results
May 23, 2024 05:30PM Titanium Transportation Group Declares Quarterly Dividend
May 23, 2024 05:29PM ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.
May 23, 2024 05:25PM MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
May 23, 2024 05:25PM MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
May 23, 2024 05:22PM HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Harbor Diversified, Inc.
May 23, 2024 05:23PM DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
May 23, 2024 05:22PM Trailblazing Dragons' Den Star Named United Nations Association in Canada's 2024 Global Citizen Laureate
May 23, 2024 05:21PM INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against Intel Corporation
May 23, 2024 05:18PM Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
May 23, 2024 05:18PM Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
May 23, 2024 05:15PM Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:13PM SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:11PM Special Olympics Florida and Orlando Health Announce Five-Year Partnership
May 23, 2024 05:10PM Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
May 23, 2024 05:09PM Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
May 23, 2024 05:06PM G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
May 23, 2024 05:05PM Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
May 23, 2024 05:05PM FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m
May 23, 2024 05:05PM NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:05PM Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
May 23, 2024 05:05PM BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:05PM Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the
May 23, 2024 05:05PM I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
May 23, 2024 05:05PM Elcora Announces Share Consolidation
May 23, 2024 05:05PM Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica
May 23, 2024 05:04PM Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
May 23, 2024 05:03PM Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024 05:01PM Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meet
May 23, 2024 05:01PM Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST
May 23, 2024 05:01PM HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024 05:00PM Timbercreek Financial Declares May 2024 Dividend
May 23, 2024 05:00PM Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024 05:00PM Canadian Premium Sand Inc. Announces Second Quarter 2024 Results
May 23, 2024 05:00PM Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
May 23, 2024 05:00PM Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:00PM Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 05:00PM Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
May 23, 2024 05:00PM Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
May 23, 2024 05:00PM Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 23, 2024 05:00PM MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT
May 23, 2024 05:00PM Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
May 23, 2024 05:00PM Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (
View Newer Stories View Older Stories